JPS5927824A - Antilipemic agent - Google Patents
Antilipemic agentInfo
- Publication number
- JPS5927824A JPS5927824A JP13653582A JP13653582A JPS5927824A JP S5927824 A JPS5927824 A JP S5927824A JP 13653582 A JP13653582 A JP 13653582A JP 13653582 A JP13653582 A JP 13653582A JP S5927824 A JPS5927824 A JP S5927824A
- Authority
- JP
- Japan
- Prior art keywords
- trimethylsteroid
- cycloartenol
- agent
- antilipemic agent
- main component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は、トリメチルステロイドを主成分とする抗脂血
剤に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an antilipemic agent containing trimethylsteroid as a main component.
β−シトステロールやカンペステロールナトの植物ステ
ロールは血清コレステ日−ルを低下させることが知られ
ており、その作用機序は一般に、腸管からのコレステロ
ール吸収阻害と考えられている。植物ステロールにその
量の’A。Plant sterols such as β-sitosterol and campesterol are known to lower serum cholesterol levels, and their mechanism of action is generally thought to be inhibition of cholesterol absorption from the intestinal tract. That amount of 'A' in plant sterols.
〜’/1ooのトリメチルステロイド、例えばシクロア
ルテノール、24−メチレンシクロアルタノールを添加
して投与すると、通常の植物ステロール剤の’Ao以下
の投与量で同等の効果を有していることが知られている
。(%開開57−18617号公報参照)。It is known that when trimethylsteroids such as cycloartenol and 24-methylenecycloartanol are added and administered at ~'Ao/1oo, the same effect is obtained at doses less than 'Ao' of ordinary plant sterol agents. It is being (See %Kokai No. 57-18617).
しかし、トリメチルステロイドを含む太豆油不ケン化物
中のアルコール類には血中コレステロール低下作用がな
いと報告されている(栄養と食糧、19巻、439頁、
1966年)、、本発明者らはトリメチルステロイド
について、その血中コレステロール低下作用を調べたと
ころ、β−シトステロールなどの植物ステロールと同等
の効果を有することが判り、本発明を完成した。However, it has been reported that alcohols in unsaponifiables of fat soybean oil, including trimethylsteroids, have no effect on lowering blood cholesterol (Nutrition and Food, Vol. 19, p. 439).
(1966), the present inventors investigated the blood cholesterol-lowering effect of trimethylsteroids and found that it had an effect equivalent to that of plant sterols such as β-sitosterol, thereby completing the present invention.
本発明で用いられるトリメチルステロイドとしては、シ
クロアルテノール、シクロアルテノール、24−メチレ
ンシクロアルタノール等を挙げることができるが、シク
ロアルテノールおよび24−メチレンシクロアルタノー
ルが特に好ましい。Examples of the trimethylsteroid used in the present invention include cycloartenol, cycloartenol, 24-methylenecycloartanol, and the like, with cycloartenol and 24-methylenecycloartanol being particularly preferred.
シクロアルテノールおよび24−メチレンシクロアルタ
ノールの調製法は特開昭57−48617号公報に記載
されている。A method for preparing cycloartenol and 24-methylenecycloartanol is described in JP-A-57-48617.
本則は、錠剤、散剤、カプセル、シロップ等の経口投与
剤形として調製される。1日の投与量ハ、成人に対して
活性成分として通常0.2〜15gであるが、好適には
0.5〜5Iである。The present invention is prepared in oral dosage forms such as tablets, powders, capsules, and syrups. The daily dose for adults is usually 0.2 to 15 g of the active ingredient, preferably 0.5 to 5 I.
実施例
平均体M125 gのウィスター系雄性ラットを用い、
コントロール群およびその他の群とも一群10匹として
22日間第1表に示す飼料を自由摂取させた。試験終了
後、ラットtエーテルで麻酔し採血を行いスベリイーウ
ェブ改良法(栄養と食糧、28巻、98負、 1975
年)により血漿コレステロール値を測定した。その結果
第1表
(単位:チ)
第2表
a:F2ft?:&ζ対しての有意差 P<o、o5本
結果によればシクロアルテノールまたは24−メチレン
シクロアルタノールを飼料中に添加することKより血漿
コレステロールが減少することは明らかである。Example Using Wistar male rats with an average weight of 125 g,
Each group of 10 animals in both the control group and other groups was allowed to freely consume the feed shown in Table 1 for 22 days. After the test, the rat was anesthetized with t-ether, blood was collected, and the improved smooth web method (Nutrition and Food, Vol. 28, 98 Negative, 1975)
Plasma cholesterol levels were measured according to 2010). As a result, Table 1 (Unit: CH) Table 2 a: F2ft? : Significant difference for &ζ P<o, o5 According to these results, it is clear that adding cycloartenol or 24-methylenecycloartanol to the feed reduces plasma cholesterol more than K.
例えはシクロアルテノールをラットおよびマウスに5J
il /Ky経口投与しても、死亡しなかった。For example, cycloartenol was administered to rats and mice by 5J.
Oral administration of il/Ky did not result in death.
〔製剤例1〕
シクロアルテノール260Ji’、ビタミン01[ll
11ク工ン酸5g、繊維素グリコール酸カルシウム20
、!i’、ラウリル硫酸ナトリウム10.!i’。[Formulation Example 1] Cycloartenol 260Ji', Vitamin 01 [ll
11 Citric acid 5g, cellulose calcium glycolate 20
,! i', sodium lauryl sulfate 10. ! i'.
ポリオキシエチレンモノステアレートsy、メチレンク
ロライド300−を取り、よく混合攪拌しケン濁液状と
する。これにアエロジル200〜400(部品名) 1
8011加えて混合攪拌後、50〜60℃で乾燥し、得
られた塊状物を砕いて吸着末を得る。この吸着末にポリ
ビニルピロリドン、2−メチル−5−ビニルピリジン−
メタアクリル酸・アクリル酸メチルエチル共重合体のよ
うな有機溶媒可溶性結合剤2011?:溶かしたクロロ
セン・エタノール溶液3001nlを加え、練合後、常
法に従いエツクペレツターで造粒、約50℃で乾燥する
と粘着性のない固形化良好な顆粒を得る(活性成分約5
1%含有)。本品に少量のステアリン酸マグネシウム等
の滑沢剤を加えることによりカプセル自動充填機で20
0mfl硬カプセルに充填することができる。Polyoxyethylene monostearate sy and methylene chloride 300- are taken, mixed well and stirred to form a cloudy liquid. Add Aerosil 200 to 400 (parts name) 1
8011 is added, mixed and stirred, and dried at 50 to 60°C, and the resulting lumps are crushed to obtain an adsorption powder. This adsorbed powder contains polyvinylpyrrolidone, 2-methyl-5-vinylpyridine-
Organic solvent soluble binder such as methacrylic acid/methyl ethyl acrylate copolymer 2011? : Add 3001 nl of the dissolved chlorocene/ethanol solution, knead, and then granulate using an Eck pelleter according to the usual method. Drying at about 50°C solidifies to obtain good granules without stickiness (active ingredients of about 5
(contains 1%). By adding a small amount of lubricant such as magnesium stearate to this product, an automatic capsule filling machine
Can be filled into 0 mfl hard capsules.
〔製剤例2〕
24−メfレンジクロアルタノール260g’a’ナタ
ネ油120 # K溶かし、常法に従ってソフトカプセ
ルに充填した。1カプセル100■で活性成分68.4
%含有。[Formulation Example 2] 260 g of 24-mef dichloroartanol was dissolved in 120 #K of 'a' rapeseed oil and filled into soft capsules according to a conventional method. 68.4 active ingredients in 1 capsule 100cm
Contains %.
〔製剤例3〕
50%ンルビトール水if 100 TnlにDKエス
テルF 160 (商品名)とポリソルベート802し
た後、蒸貿水で余情500−とし、再び攪拌して乳剤を
得る。(活性成分を約10%含有)特許出願人 三共株
式会社
代理人 弁理士樫出庄治[Formulation Example 3] DK Ester F 160 (trade name) and polysorbate 802 were added to 50% lnrbitol water if 100 Tnl, and the mixture was made to a 500% concentration with distilled water and stirred again to obtain an emulsion. (Contains about 10% active ingredient) Patent applicant: Sankyo Co., Ltd. Agent: Patent attorney Shoji Kashide
Claims (1)
24−メチレンシクロアルタノールである特許請求の範
囲第1項記載の抗脂血剤。[Claims] 1. An antilipemic agent containing trimethylsteroid as a main component. 2. The antilipemic agent according to claim 1, wherein the trimethylsteroid is cycloartenol or 24-methylenecycloartanol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13653582A JPS5927824A (en) | 1982-08-05 | 1982-08-05 | Antilipemic agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13653582A JPS5927824A (en) | 1982-08-05 | 1982-08-05 | Antilipemic agent |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS5927824A true JPS5927824A (en) | 1984-02-14 |
Family
ID=15177453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP13653582A Pending JPS5927824A (en) | 1982-08-05 | 1982-08-05 | Antilipemic agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5927824A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003021610A (en) * | 2001-07-09 | 2003-01-24 | New Cosmos Electric Corp | Odor preparing device |
JP2007139580A (en) * | 2005-11-18 | 2007-06-07 | Figaro Eng Inc | Device of generating zero-gas air for gas detection device |
US7674784B2 (en) | 2004-09-29 | 2010-03-09 | Morinaga Milk Industry Co., Ltd. | Drug and food or drink for improving hyperglycemia |
US7947669B2 (en) | 2005-09-30 | 2011-05-24 | Morinaga Milk Industry Co., Ltd. | Agent for improving insulin resistance |
-
1982
- 1982-08-05 JP JP13653582A patent/JPS5927824A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003021610A (en) * | 2001-07-09 | 2003-01-24 | New Cosmos Electric Corp | Odor preparing device |
US7674784B2 (en) | 2004-09-29 | 2010-03-09 | Morinaga Milk Industry Co., Ltd. | Drug and food or drink for improving hyperglycemia |
US7947669B2 (en) | 2005-09-30 | 2011-05-24 | Morinaga Milk Industry Co., Ltd. | Agent for improving insulin resistance |
JP2007139580A (en) * | 2005-11-18 | 2007-06-07 | Figaro Eng Inc | Device of generating zero-gas air for gas detection device |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4066756A (en) | Therapeutic compositions of 1,3-bis(2-carboxychromon-5-yloxyl)propan-2-ol and aspirin or indomethacin | |
US4254099A (en) | Pharmaceutical tablet composition | |
EP0083775B1 (en) | 5-aminosalicylic acid drug compositions that dissolve well | |
RU2627111C2 (en) | Tablet comprising dehydroepiandrosterone (dhea) | |
JPS6245845B2 (en) | ||
EP0514967A1 (en) | Low solubility drug-coated bead compositions | |
Speck et al. | Bio-availability and pharmacokinetics of cyproterone acetate-14C and ethinyloestradiol-3H after oral administration as a coated tablet (SH B 209 AB) | |
JPS6230965B2 (en) | ||
US3097139A (en) | Hypocholesterolaemia compositions | |
DE60003943T2 (en) | TRIMEGESTONE CONTAINING PHARMACEUTICAL COMPOSITIONS | |
JPH0354926B2 (en) | ||
JPS58109412A (en) | Nifedipine solid preparation | |
JPS5927824A (en) | Antilipemic agent | |
IE48133B1 (en) | A sold stable pharmaceutical composition based on 17 -ethynyl-1,3-dibenzoyloxy-7 -methyl-1,3,5(10)-oestratien-17 -ol | |
JPS5942656B2 (en) | antilipidemic agent | |
EP0521057B1 (en) | Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use | |
CA1099641A (en) | Pharmaceutical composition containing chromone derivatives | |
JPS6320409B2 (en) | ||
JPS6299323A (en) | Agent for hyperlipemia | |
US5504105A (en) | Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use | |
JPS6351122B2 (en) | ||
WO2000024388A2 (en) | Combination of 5-aminosalicylic acid and a budesonide, 6-methyl prednisolone or prednisolone for treating inflammatory disorders of the intestinal tract | |
JP4022300B2 (en) | Laxative composition | |
Tomarelli et al. | Effect of Wy-14,643 on cholesterol metabolism in normal and hypercholesterolemic rats | |
DE19645044A1 (en) | Use of ursodeoxycholic acid for the topical treatment of inflammatory diseases of the mucous membranes |